| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/28/2013 | WO2013026264A1 Cb1 acceptor inhibitor compound with nitrogen-containing aromatic ring having hydroxyl and use thereof |
| 02/28/2013 | WO2013026163A1 Hepatitis c inhibitor compounds |
| 02/28/2013 | WO2013026162A1 Hepatitis c inhibitor compounds |
| 02/28/2013 | WO2013026151A1 Improved stevia rebaudiana extract and formulation, and uses thereof |
| 02/28/2013 | WO2013026119A1 Veterinary product for treating mastitis, antibiotic and anti-inflammatory precursor compositions, kit, preparation method, use and method for treating mastitis |
| 02/28/2013 | WO2013026117A1 Non-residual, pour-on veterinary compositions, use, kit, and method for treating parasitic diseases |
| 02/28/2013 | WO2013026113A1 Use of fucosylated chondroitin sulfate, pharmaceutical composition and method for prevention and/or treatment of cancer metastasis |
| 02/28/2013 | WO2013003467A3 Methods for treating ocular inflammatory disorders |
| 02/28/2013 | WO2013003346A3 Microrna-31 compositions and methods for use in autoimmune disease |
| 02/28/2013 | WO2013003112A9 Methods and compositions for treatment of cancer and autoimmune disease |
| 02/28/2013 | WO2013002479A3 Nanoemulsion composition and method for preparing same |
| 02/28/2013 | WO2012177947A3 Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes |
| 02/28/2013 | WO2012177565A3 Regulation of macrophage activation using mir - 125b |
| 02/28/2013 | WO2012174537A3 Small molecule screening for mouse satellite cell proliferation |
| 02/28/2013 | WO2012172057A3 Use of a compound comprising at least a nucleophile function for capturing carbonyl compound resulting from the reaction between one or more compounds constituting sebum and ozone |
| 02/28/2013 | WO2012168342A9 Biopassivating membrane stabilization by means of nitrocarboxylic acid-containing phospholipids in preparations and coatings |
| 02/28/2013 | WO2012167212A3 Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current |
| 02/28/2013 | WO2012166991A8 S-nitrosylation of glucosylating toxins and uses therefor |
| 02/28/2013 | WO2012166705A3 Supramolecular nanofibers and hydrogels based on amino acid-nucleobase-glycoside conjugates |
| 02/28/2013 | WO2012166611A3 Methods for treating and preventing neutrophil-derived net toxicity and thrombosis |
| 02/28/2013 | WO2012158811A3 Purine monophosphate prodrugs for treatment of viral infections |
| 02/28/2013 | WO2012156531A9 Lysine demethylase inhibitors such as cyclylcylopropamine derivatives for use in the treatment of inflammatory diseases or conditions |
| 02/28/2013 | WO2012154837A9 The use of ketone esters for prevention of cns oxygen toxicity |
| 02/28/2013 | WO2012149157A3 Heterocyclic compounds for the inhibition of pask |
| 02/28/2013 | WO2012142125A3 Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria |
| 02/28/2013 | WO2012141615A3 Medicament |
| 02/28/2013 | WO2012139021A3 TARGETING HK alpha FOR CONTROLLING BLOOD PRESSURE AND REGULATING ELECTROLYTE BALANCE |
| 02/28/2013 | WO2012138988A3 Organometallic anti-cancer complexes |
| 02/28/2013 | WO2012125772A3 Oral formulations for promoting cellular purification |
| 02/28/2013 | WO2012125544A3 Necroptosis inhibitors and methods of use therefor |
| 02/28/2013 | WO2012117385A3 Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it |
| 02/28/2013 | WO2012116290A3 Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| 02/28/2013 | WO2012106524A3 Diagnosis and treatment of the prodromal schizophrenic state |
| 02/28/2013 | WO2012097078A3 Viscosupplementary materials |
| 02/28/2013 | WO2012079058A3 Use of jasmonate to treat bladder dysfunction |
| 02/28/2013 | WO2011115527A8 New biologically active compound n-[3-(4-nitrophenylamino)-indol-2-ylmethylene]aminoguanidine hydrochloride with anti-inflammatory activity |
| 02/28/2013 | US20130053932 Material for facilitating thermal treatments of biological tissues and method of energy targeting leading to thermal treatment of biological tissues |
| 02/28/2013 | US20130053450 Treatment of pervasive developmental disorders with redox-active therapeutics |
| 02/28/2013 | US20130053449 Method for inhibiting histone gene transcription and expression |
| 02/28/2013 | US20130053448 Therapeutic Regimens |
| 02/28/2013 | US20130053447 Desensitizing drug product |
| 02/28/2013 | US20130053446 Pharmaceutical preparations having individualized dosage and structure |
| 02/28/2013 | US20130053445 Levothyroxine Formulations |
| 02/28/2013 | US20130053444 Dp2 antagonist and uses thereof |
| 02/28/2013 | US20130053443 Method for preparing extract containing omega fatty acids from plant by using supercritical carbon dioxide extraction |
| 02/28/2013 | US20130053442 Balanced myristate- and laurate-containing edible oil |
| 02/28/2013 | US20130053441 Novel ester derivative and use thereof |
| 02/28/2013 | US20130053440 Self-Preserved Aqueous Pharmaceutical Compositions |
| 02/28/2013 | US20130053438 Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity |
| 02/28/2013 | US20130053437 Anti-inflammatory compounds |
| 02/28/2013 | US20130053436 Compounds, compositions and methods |
| 02/28/2013 | US20130053435 Methods of Treating Alcohol Intoxication, Alcohol Use Disorders and Alcohol Abuse Which Comprises the Administration of Dihydromyricetin |
| 02/28/2013 | US20130053434 Irreversible inhibitors useful for the treatment of kinase-related pathologies |
| 02/28/2013 | US20130053433 Fatty acid derivatives and analogs of drugs |
| 02/28/2013 | US20130053431 Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| 02/28/2013 | US20130053430 Modulation of cetp expression |
| 02/28/2013 | US20130053429 Treatment of Fibrosis Using Microrna 19b |
| 02/28/2013 | US20130053427 Conjugate constructs, delivery, and use for treatment of disease |
| 02/28/2013 | US20130053426 Composition For Delivery Of Genetic Material |
| 02/28/2013 | US20130053425 Method for Lowering Intraocular Pressure Using Gap Junction Blockers |
| 02/28/2013 | US20130053422 Antimicrobial Compositions |
| 02/28/2013 | US20130053420 Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients With Demyelinating and Other Nervous System Conditions |
| 02/28/2013 | US20130053419 Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors |
| 02/28/2013 | US20130053418 Acyclic organonitro compounds for use in treating cancer |
| 02/28/2013 | US20130053417 Cetp activity inhibitors |
| 02/28/2013 | US20130053416 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
| 02/28/2013 | US20130053415 Combination methods for treatment of disease |
| 02/28/2013 | US20130053414 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate |
| 02/28/2013 | US20130053413 Crystalline forms of pitavastatin calcium |
| 02/28/2013 | US20130053412 Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use |
| 02/28/2013 | US20130053411 Pharmaceutical composition and method for treating hypertension |
| 02/28/2013 | US20130053410 Substituted heteroaryl 2',3',7',7a'-tetrahydrospiro[pyrrole-3,6'-pyrrolo[1,2-c]imidazole]-1',2(1h,5'h)-dione |
| 02/28/2013 | US20130053409 2-(2,4,5-substituted-anilino) pyrimidine compounds |
| 02/28/2013 | US20130053408 Methods and compositions utilizing quinazolinones |
| 02/28/2013 | US20130053407 Pyrrolo [3,2-d] pyrimidin-3-yl derivatives used as activators of ampk |
| 02/28/2013 | US20130053406 Therapeutic compounds and uses thereof |
| 02/28/2013 | US20130053405 Carrier linked paliperidone prodrugs |
| 02/28/2013 | US20130053404 Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
| 02/28/2013 | US20130053403 Novel beta 3 adrenergic receptor agonists |
| 02/28/2013 | US20130053402 Substituted 3-thiazoloamino-propionic acid derivatives and their use as pharmaceuticals |
| 02/28/2013 | US20130053401 Thieno [2,3-b] pyridinedione activators of ampk and therapeutic uses thereof |
| 02/28/2013 | US20130053400 Oligomer-antihistamine conjugates |
| 02/28/2013 | US20130053399 Methods of administering antihistamines |
| 02/28/2013 | US20130053398 Modulators of fatty acid amide hydrolase |
| 02/28/2013 | US20130053397 Indoles |
| 02/28/2013 | US20130053396 Piperidine and piperazine derivatives as smo antagonists |
| 02/28/2013 | US20130053395 Pyrazolopyridine kinase inhibitors |
| 02/28/2013 | US20130053394 Pyrazolopyrimidine kinase inhibitors |
| 02/28/2013 | US20130053393 Methods and compositions for treating peripheral vascular disease |
| 02/28/2013 | US20130053392 Carbonic anhydrase inhibitors |
| 02/28/2013 | US20130053391 Treatment of T-Cell Lymphoma using 10-propargyl-10-deazaaminopterin |
| 02/28/2013 | US20130053390 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives |
| 02/28/2013 | US20130053389 Certain chemical entities, compositions and methods |
| 02/28/2013 | US20130053388 Pyrazolopyrazine kinase inhibitors |
| 02/28/2013 | US20130053387 Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents |
| 02/28/2013 | US20130053386 Diaryl ether derivatives as notch sparing gamma secretase inhibitors |
| 02/28/2013 | US20130053384 Certain Chemical Entities, Compositions, and Methods |
| 02/28/2013 | US20130053383 Indazoles |
| 02/28/2013 | US20130053382 Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) |
| 02/28/2013 | US20130053381 2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl-sulfonamide derivatives |